D. E. Shaw & Co., Inc. C4 Therapeutics, Inc. Transaction History

D. E. Shaw & Co., Inc.

$125 Billion
Q2 2025

A detailed history of D. E. Shaw & Co., Inc. transactions in C4 Therapeutics, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 89,475 shares of CCCC stock, worth $220,108. This represents 0.0% of its overall portfolio holdings.

Number of Shares

89,475

Previous 79,275 12.87%

Holding current value

$220,108

Previous $126,000 0.79%

% of portfolio

0.0%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$1.1 - $1.74 $11,220 - $17,748	10,200 Added 12.87%	89,475 $127,000
Q1 2025 May 15, 2025	BUY	$1.6 - $4.09 $4,473 - $11,435	2,796 Added 3.66%	79,275 $126,000
Q4 2024 Feb 14, 2025	SELL	$3.6 - $7.0 $152,686 - $296,891	-42,413 Reduced 35.67%	76,479 $275,000
Q3 2024 Nov 14, 2024	SELL	$4.43 - $7.38 $1.05 Million - $1.75 Million	-237,320 Reduced 66.62%	118,892 $677,000
Q2 2024 Aug 14, 2024	SELL	$4.05 - $8.1 $568,340 - $1.14 Million	-140,331 Reduced 28.26%	356,212 $1.65 Million
Q1 2024 May 15, 2024	BUY	$5.3 - $11.0 $1.34 Million - $2.78 Million	252,905 Added 103.8%	496,543 $4.06 Million
Q4 2023 Feb 14, 2024	SELL	$1.18 - $6.03 $224,756 - $1.15 Million	-190,472 Reduced 43.88%	243,638 $1.38 Million
Q3 2023 Nov 14, 2023	SELL	$1.81 - $3.89 $153,974 - $330,918	-85,069 Reduced 16.39%	434,110 $807,000
Q2 2023 Aug 14, 2023	BUY	$2.75 - $3.77 $893,799 - $1.23 Million	325,018 Added 167.4%	519,179 $1.43 Million
Q1 2023 May 15, 2023	BUY	$3.1 - $9.02 $335,420 - $975,964	108,200 Added 125.87%	194,161 $609,000
Q4 2022 Feb 14, 2023	SELL	$5.42 - $10.24 $239,135 - $451,799	-44,121 Reduced 33.92%	85,961 $507,000
Q3 2022 Nov 14, 2022	BUY	$8.03 - $12.77 $411,890 - $655,024	51,294 Added 65.1%	130,082 $1.14 Million
Q2 2022 Aug 15, 2022	BUY	$5.06 - $26.46 $398,667 - $2.08 Million	78,788 New	78,788 $594,000
Q1 2022 May 16, 2022	SELL	$19.99 - $33.23 $514,442 - $855,174	-25,735 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$29.39 - $46.86 $465,890 - $742,824	15,852 Added 160.4%	25,735 $829,000
Q3 2021 Nov 15, 2021	SELL	$35.91 - $50.5 $238,765 - $335,774	-6,649 Reduced 40.22%	9,883 $442,000
Q2 2021 Aug 16, 2021	BUY	$30.39 - $42.18 $337,389 - $468,282	11,102 Added 204.46%	16,532 $626,000
Q1 2021 May 17, 2021	SELL	$31.96 - $46.5 $228,322 - $332,196	-7,144 Reduced 56.82%	5,430 $201,000
Q4 2020 Feb 16, 2021	BUY	$22.8 - $37.05 $286,687 - $465,866	12,574 New	12,574 $417,000

Others Institutions Holding CCCC

# of Institutions

102

Shares Held

57.2M

Call Options Held

15.2K

Put Options Held

View Full List

About C4 Therapeutics, Inc.

Ticker CCCC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,913,800
Market Cap $120M
Description
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...

More about CCCC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account